South Ko­re­an reg­u­la­tor sus­pends Sam­sung Bi­o­Log­ic­s' stock, cit­ing ac­count­ing vi­o­la­tions

Sam­sung’s biotech arm Sam­sung Bi­o­Log­ics in­flat­ed its val­ue ahead of its 2016 list­ing, will­ful­ly breach­ing ac­count­ing stan­dards, South Ko­rea’s fi­nan­cial reg­u­la­tor has found, cap­ping months …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.